A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Virology
Robert B MandellRamon Flick

Abstract

Virus-like particles (VLPs) present viral antigens in a native conformation and are effectively recognized by the immune system and therefore are considered as suitable and safe vaccine candidates against many viral diseases. Here we demonstrate that chimeric VLPs containing Rift Valley fever virus (RVFV) glycoproteins G(N) and G(C), nucleoprotein N and the gag protein of Moloney murine leukemia virus represent an effective vaccine candidate against Rift Valley fever, a deadly disease in humans and livestock. Long-lasting humoral and cellular immune responses are demonstrated in a mouse model by the analysis of neutralizing antibody titers and cytokine secretion profiles. Vaccine efficacy studies were performed in mouse and rat lethal challenge models resulting in high protection rates. Taken together, these results demonstrate that replication-incompetent chimeric RVF VLPs are an efficient RVFV vaccine candidate.

References

Oct 1, 1988·Microbial Pathogenesis·G W Anderson, C J Peters
Jan 1, 1988·Archives of Virology·C J PetersT W Slone
Apr 1, 1987·Microbial Pathogenesis·G W AndersonC J Peters
Mar 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·Y YoshinakaS Oroszlan
Oct 1, 1985·The Journal of General Virology·H CaplenD H Bishop
Jan 12, 1984·Nature·W J McAleerM R Hilleman
Dec 1, 1996·The Journal of Cell Biology·M SuomalainenH Garoff
Apr 8, 2000·Current Opinion in Structural Biology·J E Johnson, W Chiu
Mar 22, 2002·Journal of Virology·Anthony P SchmittRobert A Lamb
Dec 25, 2002·Emerging Infectious Diseases·Trevor ShoemakerStuart T Nichol
Jan 23, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mohammed Al-HazmiAli Aqeel
Mar 5, 2003·International Journal of Antimicrobial Agents·Hanan H Balkhy, Ziad A Memish
May 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Kazumoto MurataT Jake Liang
Sep 19, 2003·Trends in Microbiology·Rob Noad, Polly Roy
Sep 23, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Carol O TacketMary K Estes
Oct 3, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tariq A MadaniOsama Shobokshi
Dec 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Kelly L WarfieldSina Bavari
Aug 11, 2004·Virology·Catharine M BosioSina Bavari
Nov 25, 2004·Current Opinion in Biotechnology·Robert L Garcea, Lutz Gissmann

❮ Previous
Next ❯

Citations

Mar 22, 2014·PLoS Neglected Tropical Diseases·Shin MurakamiShinji Makino
Oct 18, 2014·Vector Borne and Zoonotic Diseases·Bonto FaburayJuergen A Richt
Apr 1, 2011·Journal of Virology·Hani BoshraAlejandro Brun
Jun 15, 2011·Viruses·Tetsuro Ikegami, Shinji Makino
Aug 30, 2011·Proceedings of the National Academy of Sciences of the United States of America·James F PapinTilahun D Yilma
Sep 6, 2011·Emerging Infectious Diseases·Jeroen KortekaasRob J M Moormann
Oct 1, 2011·Journal of Virology·Jeroen KortekaasRob J M Moormann
Sep 22, 2010·Vector Borne and Zoonotic Diseases·Jeroen KortekaasRob J M Moormann
Jun 19, 2013·Current Opinion in Virology·Darryl Falzarano, Heinz Feldmann
Nov 17, 2011·Virus Research·Ted M RossDarci R Smith
Jun 15, 2011·Vaccine·Beate von TeichmanMichele Bouloy
Jul 27, 2010·Journal of Virological Methods·Robert B MandellRamon Flick
Mar 19, 2014·Vaccine·Diego FontanaClaudio Prieto
Apr 20, 2012·The Journal of General Virology·Emna Ayari-FakhfakhCatherine Cêtre-Sossah
Feb 19, 2015·Biotechnology Journal·Gorben P Pijlman
May 30, 2015·Virus Research·Kaori TerasakiShinji Makino
Apr 3, 2012·Current Opinion in Virology·Brian H Bird, Stuart T Nichol
Apr 1, 2014·Antiviral Research·Jeroen Kortekaas
Jul 14, 2016·Virologica Sinica·Jinliang LiuFei Deng
Sep 20, 2017·Vaccines·Bonto FaburayJuergen A Richt
Dec 18, 2013·Journal of Virology·Rodrigo AcuñaNicole D Tischler
Nov 30, 2018·Biotechnology Journal·Sandiswa MbewanaEdward P Rybicki
Jan 1, 2019·Biotechnology and Bioengineering·Hayley K Charlton HumeLinda H L Lua
Mar 19, 2013·Zoonoses and Public Health·R KoukuntlaR Flick
Sep 30, 2010·Clinical and Vaccine Immunology : CVI·Reuben K SoiTimothy B Crawford
Mar 27, 2020·Current Topics in Medicinal Chemistry·Prasad MinakshiGaya Prasad
Oct 7, 2020·EFSA Journal·Søren Saxmose NielsenGabriele Zancanaro
Feb 27, 2021·Journal of Nanobiotechnology·Saghi NooraeiGholamreza Ahmadian
Apr 6, 2021·Journal of Veterinary Research·Małgorzata KwaśnikJerzy Rola

❮ Previous
Next ❯

Datasets Mentioned

BETA
GQ148915

Methods Mentioned

BETA
transfection
transmission electron microscopy
density gradient fractionation
immunoprecipitation
PCR
transfections
flow filtration

Clinical Trials Mentioned

NCT00415051

Software Mentioned

ImageJ

Related Concepts

Related Feeds

BK Virus Infection

BK virus infection is a significant complication of modern immunosuppression used in kidney transplantation. Discover the latest research on BK virus infection here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.